WNT7B, a WNT ligand, is involved in a number of cancers and contributes to drug resistance in several types of malignancies by activating canonical WNT signaling, including gemcitabine resistance in pancreatic cancer, cis-platinum resistance in cervical cancer, and doxorubicin resistance in osteosarcoma [14,15,16]. This evidence concerns the gene WNT7B and pancreatic neoplasm.